|
Real-world characteristics and outcomes of patients with advanced non-small cell lung cancer (aNSCLC) receiving immune checkpoint inhibitor. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Celgene; Concerto HealthAI |
Stock and Other Ownership Interests - Celgene |
|
|
Employment - Concerto HealthAI |
Stock and Other Ownership Interests - Concerto HealthAI |
|
|
No Relationships to Disclose |
|
|
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); HERON (Inst); Lilly (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Merck KGaA (Inst); Pfizer (Inst); Sanofi (Inst) |
|
George Anthony Komatsoulis |
No Relationships to Disclose |
|
|
Employment - Concerto HealthAI |
|
|
|
|
Stock and Other Ownership Interests - Tempus |
Patents, Royalties, Other Intellectual Property - Tempest Therapeutics |
|
|
|
Stock and Other Ownership Interests - Tempus |
Patents, Royalties, Other Intellectual Property - Tempus |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb |
Research Funding - Amgen (Inst); AstraZeneca (Inst); Eisai (Inst); Genentech (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
|
|
No Relationships to Disclose |